Editorial

You have full text access to this OnlineOpen article

Atherothrombotic comorbidity in the rheumatic diseases. The evidence becomes clearer. What should clinicians do?

  1. Inmaculada del Rincón*

Article first published online: 29 SEP 2009

DOI: 10.1002/art.24875

Issue

Arthritis Care & Research

Arthritis Care & Research

Volume 61, Issue 10, pages 1284–1286, 15 October 2009

Additional Information

How to Cite

del Rincón, I. (2009), Atherothrombotic comorbidity in the rheumatic diseases. The evidence becomes clearer. What should clinicians do?. Arthritis & Rheumatism, 61: 1284–1286. doi: 10.1002/art.24875

Author Information

  1. University of Texas Health Science Center, San Antonio

*University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229

Publication History

  1. Issue published online: 29 SEP 2009
  2. Article first published online: 29 SEP 2009
  3. Manuscript Accepted: 1 JUL 2009
  4. Manuscript Received: 23 JUN 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (52K)

REFERENCES

  • 1
    Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60: 221–5.
  • 2
    Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 338–46.
    Direct Link:
  • 3
    Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408–15.
  • 4
    Shah MA, Shah AM, Krishnan E. Poor outcomes after acute myocardial infarction in systemic lupus erythematosus. J Rheumatol 2009; 36: 570–5.
  • 5
    Hak AE, Karlson EW, Feskanich D, Stampfer MJ, Costenbader KH. Systemic lupus erythematosus and risk of cardiovascular disease: results from the Nurses' Health Study. 2009; 61: 1396–1402.
  • 6
    Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, et al, and the American Heart Association. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004; 109: 672–93.
  • 7
    Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al, the American Heart Association/American College of Cardiology, and the National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006; 47: 2130–9.
  • 8
    Wallace DJ. Improving the prognosis of SLE without prescribing lupus drugs and the primary care paradox. Lupus 2008; 17: 91–2.
  • 9
    Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes mellitus and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–34.
  • 10
    Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141: 764–70.
  • 11
    Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol 2007; 157: 545–59.
  • 12
    Del Rincon I, O'Leary DH, Haas RW, Escalante A. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum 2004; 50: 3813–22.
    Direct Link:
  • 13
    The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324: 150–4.
  • 14
    Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007; 66: 1168–72.
  • 15
    Clark P, Casas E, Tugwell P, Medina C, Gheno C, Tenorio G, et al. Hydroxychloroquine compared with placebo in rheumatoid arthritis: a randomized controlled trial. Ann Intern Med 1993; 119: 1067–71.
  • 16
    Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 2009; 68: 238–41.
  • 17
    Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009; 61: 29–36.
    Direct Link:
  • 18
    Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990; 89: 322–6.
  • 19
    Kavanaugh A, Adams-Huet B, Jain R, Denke M, McFarlin J. Hydroxychloroquine effects on lipoprotein profiles (the HELP trial): a double-blind, randomized, placebo-controlled, pilot study in patients with systemic lupus erythematosus. J Clin Rheumatol 1997; 3: 3–8.
  • 20
    Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, et al. Hydroxychloroquine and risk of diabetes mellitus in patients with rheumatoid arthritis. JAMA 2007; 298: 187–93.
  • 21
    Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1997; 96: 2751.
  • 22
    Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973–9.
  • 23
    Brown MS, Goldstein JL. Lowering LDL: not only how low, but how long? Science 2006; 311: 1721–3.
  • 24
    Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al, the National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, and American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227–39.
  • 25
    Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al, and the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195–207.
  • 26
    Ridker PM, Solomon DH. Should patients with rheumatoid arthritis receive statin therapy? [editorial]. Arthritis Rheum 2009; 60: 1205–9.
    Direct Link:
  • 27
    Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89–118.
  • 28
    Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003; 170: 1524–30.
  • 29
    McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004; 363: 2015–21.
  • 30
    Maki-Petaja KM, Booth AD, Hall FC, Wallace SM, Brown J, McEniery CM, et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007; 50: 852–8.
  • 31
    Zapolska-Downar D, Siennicka A, Kaczmarczyk M, Kolodziej B, Naruszewicz M. Simvastatin modulates TNFα-induced adhesion molecules expression in human endothelial cells. Life Sci 2004; 75: 1287–302.
  • 32
    Jick SS, Choi H, Li L, McInnes IB, Sattar N. Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis 2009; 68: 546–51.
  • 33
    Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399–402.
View Full Article (HTML) Get PDF (52K)